Skip to main content

Table 1 Patients’ characteristics on baseline

From: Telemedicine-assisted structured self-monitoring of blood glucose in management of T2DM results of a randomized clinical trial

Characteristics

Telemedicine(212)

Control(206)

p value*

Age (years)

52.1 ± 9.2

51.8 ± 8.3

0.68

Males (%)

62(45.5)

48(47.5)

0.85

Diabetes duration (years)

7.4 ± 1.5

7.2 ± 1.5

0.46

FBG (mmol/L)

7.1 ± 1.6

7.0 ± 1.6

0.75

2hPBG (mmol/L)

9.7 ± 2.3

9.6 ± 2.2

0.69

HbA1c (%)

7.9 ± 0.9

8.0 ± 0.9

0.56

BMI (Kg/m2)

24.6 ± 1.9

24.2 ± 1.5

0.18

Systolic BP (mmHg)

125.4 ± 13.3

125.5 ± 13.9

0.95

Diastolic BP (mmHg)

76.6 ± 9.1

77.17 ± 10.8

0.84

Triglycerides (mmol/L)

2.4 ± 0.8

2.6 ± 1.0

0.40

Total cholesterol (mmol/L)

5.4 ± 0.7

5.5 ± 0.8

0.91

HDL cholesterol (mmol/L)

1.1 ± 0.4

1.1 ± 0.3

0.95

LDL cholesterol (mmol/L)

3.7 ± 0.7

3.8 ± 0.8

0.79

Glucose control methods

OAD only

97(0.71)

78(0.77)

0.64

Insulin only

2(0.01)

1(0.01)

0.51

OAD + insulin

38(0.28)

22(0.22)

0.48

Educational status

Elementary

34(25)

26(25.7)

0.55

Middle

73(53.6)

56(55.4)

0.68

High

27(19.8)

18(17.8)

0.29

College

2(1.4)

1(0.9)

0.17

Testing

frequency(times/month)

1.9 ± 0.3

1.7 ± 0.6

0.86

  1. Data are means ± SD or n (%). FBG, fasting blood glucose; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OAD, oral hypoglycemic drugs
  2. *P<0.05